Plymouth Meeting-based Inovio Pharmaceuticals is currently in talks with large drugmakers to secure prompt delivery of its coronavirus vaccine if the development is successful, writes James Paton for the Bloomberg.

The biotech company aims to have a minimum of 1 million doses available by the end of this year and then rely on larger manufacturers to grow that number to as many as 50 million. However this still depends on it clearing several hurdles, including studies of the vaccine in humans that are scheduled to begin by late spring or early summer.

“We’re running as fast as we can,” said Inovio Chief Executive Officer J. Joseph Kim.

Inovio has been backed by up to $9 million in funds from the Norway-based Coalition for Epidemic Preparedness Innovations to accelerate the development of the vaccine.

However, the company will not be able to produce a vaccine in large quantities and would need the resources and scale of a much larger company.

“We’re proactively establishing additional relationships” to scale up manufacturing, said Kim.

Still, he did not disclose the names of any potential partners at this time.

Read more about at the Bloomberg by clicking here.

_______

Top photo credit: Ben Taylor55 Coronavirus via photopin (license)

.

[uam_ad id=”64837″]